Rodriguez-Otero P, Voorhees PM, Boccadoro M, Laubach J, Einsele H, Sborov DW, Dimopoulos MA, Broijl A, Mina R, Spencer A, Schjesvold F, Silbermann R, Gay F, Costa LJ, Perrot A, Liu Y, Wang J, Sitthi-Amorn A, Carson R, Cortoos A, Usmani SZ, Richardson PG, Moreau P, Sonneveld P, Kaufman JL (2025)
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Clin Lymphoma Myeloma Leuk (in press)
DOI 10.1016/j.clml.2025.04.007, PubMed 40360369

Holstein SA, Atrash S, Mian H, Dimopoulos MA, Schjesvold F, Popat R, Shah N, Gatt ME, Gocke CB, Frenzel L, Touzeau C, Beksac M, Manier S, Magen H, Travis P, Nadeem O, Suryanarayan K, Li C, Li S, Nelson A, Cherepanov D, Parot X, Vogl DT (2025)
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma
Blood (in press)
DOI 10.1182/blood.2024027873, PubMed 40279508

Gundesen MT, Schjesvold F, Lund T (2025)
Treatment of myeloma bone disease: When, how often, and for how long?
J Bone Oncol, 52, 100680
DOI 10.1016/j.jbo.2025.100680, PubMed 40242221